Late dyskinesia: latest news - GoINPHARMA
Tuesday, 11 December 2018 - 23:37

Late dyskinesia

FDA approves Austedo, Teva’s treatment for tardive dyskinesia

Teva Pharmaceutical announced that FDA has approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. The product was already approved last April for the treatment of chorea associated with Huntington’s disease. Tardive dyskinesia is a disabling and…

Positive data for Teva’s SD-809 in Tardive Dyskinesia

Teva Pharmaceutical Industries has announced that SD-809 (deutetrabenazine) showed statistically significant results in the second Phase III AIM-TD registration trial designed to evaluate the product for the treatment of tardive dyskinesia. These results follow positive data from the ARM-TD trial…